Micron's Memory Is Sold Out Through 2027 — and the Scarcity Is Just Getting Started

Micron's entire high-bandwidth memory output is sold out — not just for this year, but through the end of 2027. At KeyBanc's Technology Leadership Forum in August, Chief Commercial Officer Sumit Sadana told investors the AI memory crunch isn't easing: calendar 2027 will be even tighter than 2026, and the company has no visibility on when supply finally catches up.

This flips the memory industry's oldest rule. For three decades, DRAM behaved like a commodity — every boom invited new capacity, and every new fab crushed prices back to earth. The AI buildout has turned that script upside down. Every GPU cluster needs HBM stacked on the package like a skyscraper, and there simply isn't enough capacity in the world to make it.

Here's the part most people miss: the more HBM Micron ships, the tighter ordinary DRAM gets. Every 100 bits of HBM3E the company produces removes roughly 300 bits of conventional DDR capacity — a three-to-one cannibalization — and that ratio could approach four-to-one once HBM4E ramps. HBM is the best use of the wafer, so it gets the wafer, and the rest of the market pays the price. That's why the company's entire 2026 HBM supply sits under fixed-price, multi-year contracts, with HBM3E and HBM4 already fully booked through the end of 2027.

Customers aren't just buying — they're pre-committing. Micron has signed roughly $22 billion in commitments across 16 strategic agreements, good for about $100 billion in cumulative minimum prices through 2030. The company also raised its U.S. manufacturing investment to roughly $250 billion through 2035, targeting about 40% of its DRAM produced on home soil. As the only U.S.-based DRAM and HBM maker, that positioning keeps getting more valuable by the quarter. The latest reported quarter carried an operating margin around 81%, and Micron is reinvesting the windfall: its venture arm just launched a $250 million fund spanning the full AI stack.

Here's what fixed-price contracts do to the income statement: they turn a famously cyclical business into something close to an annuity. Customers who locked in prices can't renegotiate when spot markets spike, and Micron doesn't have to worry about a demand air pocket in 2027 — the revenue is already contracted. That's why the forward earnings multiple looks absurd next to the growth on the books, and why management keeps hammering the same message: the crunch runs well past 2027.

Wall Street is still catching up. UBS reiterated its Buy rating with a street-high target of $1,625 — up from $535 — after lifting its 2027 HBM price assumption to growth of 50% year over year, and it sees DRAM undersupply lasting through at least the second quarter of calendar 2028. The HBM market itself is now expected to reach roughly $100 billion by 2028, compounding at about 40% a year from roughly $35 billion in 2025 — two years earlier than anyone previously modeled, and larger than the entire DRAM market of 2024. In other words: the most important memory product on Earth is becoming a market bigger than all of DRAM was two years ago.

The bear case, such as it is, comes from the sidelines. Apple is reportedly testing DRAM from China's CXMT as a supply-diversification hedge — a reminder that scarcity eventually funds competitors. That is a 2028 problem, though. Right now the market is pricing Micron at roughly 6 times forward earnings, with about $19.6 billion in net cash on the balance sheet. A company generating this much cash, trading this cheaply, with its product sold out two years in advance? The competition will come. It just hasn't arrived yet.

Memory has flipped from commodity to strategic choke point, and Micron is the purest way to own the scarcity. The stock has multiplied more than sevenfold over the past year, and analysts are still running behind the fundamentals. In a market where everyone pays 40 times earnings for AI exposure, the one company that is actually sold out trades at 6.

Disclosure: The Signal holds no position in MU. Positions may change. This is not financial advice.